Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Despite the development of new therapeutic agents for the treatment of mood disorders, drug tolerability remains a major barrier to effective treatment for many patients. Pharmacogenomic studies aim to identify genetic markers that moderate drug response and tolerability, with the intention that this information will aid in drug selection and dosing. The serotonin-2A receptor gene (HTR2A) is one attractive candidate gene for pharmacogenomic studies of drugs for mood disorders.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi